

# Albumin binding of insulins acylated with fatty acids: characterization of the ligand–protein interaction and correlation between binding affinity and timing of the insulin effect *in vivo*

Peter KURTZHALS\*, Svend HAVELUND, Ib JONASSEN, Benedicte KIEHR, Ulla D. LARSEN, Ulla RIBEL and Jan MARKUSSEN

Novo Research Institute, Novo Nordisk A/S, Novo Alle, DK-2880 Bagsvaerd, Denmark

Albumin is a multifunctional transport protein that binds a wide variety of endogenous substances and drugs. Insulins with affinity for albumin were engineered by acylation of the  $\epsilon$ -amino group of Lys<sup>B29</sup> with saturated fatty acids containing 10–16 carbon atoms. The association constants for binding of the fatty acid acylated insulins to human albumin are in the order of  $10^4$ – $10^5$  M<sup>-1</sup>. The binding apparently involves both non-polar and ionic interactions with the protein. The acylated insulins bind at the long-chain fatty acid binding sites, but the binding affinity is lower than that of the free fatty acids and depends to a relatively small degree on the number of carbon atoms in the fatty acid

chain. Differences in affinity of the acylated insulins for albumin are reflected in the relative timing of the blood-glucose-lowering effect after subcutaneous injection into rabbits. The acylated insulins provide a breakthrough in the search for soluble, prolonged-action insulin preparations for basal delivery of the hormone to the diabetic patient. We conclude that the biochemical concept of albumin binding can be applied to protract the effect of insulin, and suggest that derivatization with albumin-binding ligands could be generally applicable to prolong the action profile of peptide drugs.


## INTRODUCTION

The therapeutic applicability of a biologically active peptide depends on the possibility of delivering it at its site of action with a suitable time-profile. Peptide and protein drug delivery is associated with several problems [1]. For example, peptides must in general be administered by injection because they are susceptible to enzymic breakdown and penetrate poorly through mucosal membranes. Furthermore, most peptides have a short half-life within the circulation and must be gradually released into the bloodstream to have a sustained effect. Advanced controlled-delivery systems for peptides, such as pumps, liposomes and microspheres, have not proved successful [2].

Insulin is a peptide hormone that has been in clinical use for decades. To meet the requirement for a constant basal supply of the hormone, diabetic patients receive daily subcutaneous injections

of long-acting insulin suspensions [3]. In recent years, much effort has been devoted to the development of soluble, long-acting insulin analogues with a more reproducible and a more prolonged effect than the insulin suspensions [4–6], but no analogues have shown improved clinical results.

Albumin is a multifunctional transport protein that binds reversibly a wide variety of endogenous substances and drugs [7–10]. Owing to the restricted passage of albumin–drug complexes across membranes, the pharmacokinetic parameters of many drugs can be altered by modification of their affinity for albumin [11,12]. To test whether albumin binding can be applied to protract the effect of peptide drugs, we have engineered insulin derivatives with affinity for albumin by acylation of the hormone with fatty acids (Figure 1). In the present study we investigate the interaction between the fatty acid acylated insulins and human serum albumin (HSA), using albumin immobilized on agarose. Differences in affinity of acylated insulins for albumin are correlated to the relative degree of protraction of the insulins in rabbits. The suitability of using albumin binding to protract insulin action is discussed.



**Figure 1** Schematic representation of the fatty acid acylated insulins

R denotes the fatty acid attached by an amide bond to the  $\epsilon$ -amino group of Lys<sup>B29</sup>. In the present study we have prepared derivatives of des-(B30) human insulin (X is deleted) in which R has from 10 to 16 carbon atoms, and analogues of human insulin (X is Thr) in which R has 10 or 14 carbon atoms.

## EXPERIMENTAL

### Materials

Fatty acid-free (< 0.005%) and globulin-free HSA purchased from Sigma were used throughout this study. Fatty acids of analytical grade were from Fluka AG (Switzerland) or Aldrich (Germany). Divinylsulphone-activated Sepharose 6B (Mini-Leak Low) was obtained from Kem-En-Tec A/S (Copenhagen, Denmark). Insulin Protaphane (NPH-insulin) and human insulin were supplied by Novo Nordisk A/S (Denmark). Des-(B30) human insulin was prepared as previously described [13]. [9,10-<sup>3</sup>H]Myristic acid (33.5 Ci/mmol) was supplied as an ethanolic

Abbreviations used: Boc, t-butyloxycarbonyl; HSA, human serum albumin; NPH-insulin, Neutral Protamine Hagedorn insulin (Insulin Protaphane);

solution (1 mCi/ml) from DuPont NEN. All other chemicals used were of reagent grade or better.

Protein concentrations were determined by UV absorbance, taking molar absorption coefficients of  $\epsilon_{279}$   $35.7 \times 10^3 \text{ M}^{-1} \cdot \text{cm}^{-1}$  for HSA [7] and  $\epsilon_{276}$   $6.2 \times 10^3 \text{ M}^{-1} \cdot \text{cm}^{-1}$  for the insulins.

#### Preparation of fatty acid acylated insulins

Human insulin and des-(B30) human insulin were treated with di-*t*-butyldicarbonate in DMSO/triethylamine (20:1, v/v), and the Gly<sup>A1</sup>, Phe<sup>B1</sup> di-Boc (where Boc represents *t*-butyloxy-carbonyl) insulins were separated from the isomers by reversed-phase HPLC. The hydroxysuccinimide esters of fatty acids were prepared from fatty acids and *N*-hydroxysuccinimide by using dicyclohexylcarbodiimide in dimethylformamide for ester formation, and ethanol for recrystallization of the products. The  $\epsilon$ -amino group of Lys<sup>B29</sup> was selectively acylated by treatment of Gly<sup>A1</sup>, Phe<sup>B1</sup> di-Boc insulin with the fatty acid hydroxysuccinimide esters in dimethylformamide/DMSO (1:7, v/v) at 15 °C, using 20 equivalents of a tertiary amine such as 4-methylmorpholine. The protecting groups were removed with trifluoroacetic acid and the Lys<sup>B29</sup>-acylated insulins were purified by reversed-phase HPLC. The identity of the fatty acid acylated insulins was confirmed by mass spectrometry, determining the molecular mass of the insulin derivative, of the B-chain after treatment with dithiothreitol, and of the B-chain fragment containing Lys<sup>B29</sup> obtained by treatment with *Staphylococcus aureus* protease.

Mono <sup>125</sup>I-(Tyr<sup>A14</sup>)-labelled insulins were prepared as previously described [14].

#### Immobilization of HSA

HSA was coupled to the activated agarose matrix (Mini-Leak Low) according to the guidelines of the manufacturer. For each gram of gel was added 2 ml of 5% (w/v) HSA and 2 ml of 30% (w/v) PEG 20000 in 0.3 M NaHCO<sub>3</sub>, pH 8.6. The suspension was gently agitated overnight at 23 °C. Excess active groups were blocked by treatment with 30 mM ethanolamine at pH 9.0 for 5 h at 23 °C. The molar content of HSA in the gel was 0.4–0.6 nmol per mg suction-dried gel as determined by titration with HSA in solution as described below. At pH 8.6, amino groups and thiol groups can be coupled to the activated matrix, whereas hydroxyl groups react at pH > 10 [15]. Because HSA contains 59 lysine residues and a single free cysteine [7], the coupling is expected to involve primarily  $\epsilon$ -amino groups of lysine residues.

#### Equilibration of ligands with immobilized HSA

Immobilized HSA was washed with 2–3 volumes of 0.1 M Tris, pH 7.4, on a suction filter and drained until cracks were seen in the gel. A portion of the gel was weighed out and suspended in 0.1 M Tris, pH 7.4, containing 0.025% (v/v) Triton X-100 (Tris/TX-100). The concentration of immobilized HSA in the suspension was less than 40 mg/ml. The exclusion volume provided by the Mini-Leak matrix (less than 4% of the total volume) is considered to be insignificant. Portions of the suspension were pipetted into vials during stirring and combined with the radiolabelled ligand and Tris/TX-100 to give a final volume of 1.00 ml. When binding was examined in the presence of fatty acid or albumin in solution, these components were included in the mixture before Tris/TX-100 was added to the final volume of 1.00 ml. The concentration of radioactivity in the

5 min at 1800 g. Incubation for 2 h was found to be sufficient to reach equilibrium.

When <sup>125</sup>I-labelled ligands were used, the total radioactivity in each vial (*T*) and the radioactivity in 500  $\mu$ l of supernatant ( $\frac{1}{2}$ *F*) were counted on a Packard Cobra Auto-Gamma instrument (Packard, Meriden, U.S.A.). The bound radioactivity (*B*) was determined as  $B = T - F$ .

When <sup>3</sup>H-labelled myristic acid was used, 500  $\mu$ l of supernatant was transferred to a scintillation counting vial, 10 ml Ultima Gold (Packard) was added, and the radioactivity ( $\frac{1}{2}$ *F*) was counted on a Packard Tri-Carb liquid scintillation analyser. In this case, the total radioactivity in each vial was estimated from a measurement of the radioactivity ( $\frac{1}{2}$ *T*) in 500  $\mu$ l of a mixture treated as described above but in the absence of immobilized albumin.

No unspecific binding was seen when radiolabelled acylated insulins were incubated as described above with Mini-Leak Low blocked with ethanolamine. Triton X-100 was included in the buffer to prevent non-specific binding of the acylated insulins to vials and pipettes. By varying the concentration of the detergent between 0 and 0.025% (v/v) it was found that 0.025% (v/v) Triton X-100 prevented non-specific binding without affecting the binding to albumin.

#### Titration of immobilized HSA for binding of fatty acids

A weighed amount (about 25 mg/ml) of immobilized HSA (HSA<sub>imm</sub>) was equilibrated with 1.5 nM [9,10-<sup>3</sup>H]myristic acid and varying concentrations (1–40  $\mu$ M) of HSA in solution (HSA<sub>free</sub>). As HSA<sub>free</sub> is present in large molar excess over [9,10-<sup>3</sup>H]myristic acid, a plot of *F/B* against [HSA<sub>free</sub>] is linear. Assuming that the binding constants to HSA<sub>imm</sub> and HSA<sub>free</sub> are equal, the slope of the line is 1/[HSA<sub>imm</sub>]. The molar content of HSA per mg of suction-dried gel is calculated from the amount of gel in the suspension (about 25 mg/ml) and [HSA<sub>imm</sub>]. In one case, the albumin content of a hydrolysed sample of Mini-Leak HSA was determined by amino acid analysis. The amino acid analysis showed a 20% higher albumin content than found by titration, indicating that the binding properties of HSA are not completely unaffected by immobilization. It has previously been shown that a similar coupling of albumin to agarose does not alter the primary binding sites for most ligands, including fatty acids [16].

#### Receptor affinity

Relative affinities of <sup>125</sup>I-(Tyr<sup>A14</sup>)-labelled insulins for the soluble insulin receptor were determined by a modification of a previously described assay [17]. In brief, the soluble insulin receptor was immobilized on Mini-Leak to a concentration of 1  $\mu$ M in the gel. Various concentrations (0–20 nM) of immobilized receptor were equilibrated with 10 pM of the radiolabelled insulin in a binding buffer (pH 7.8) containing 0.1 M Hepes, 0.1 M NaCl, 0.01 M MgCl<sub>2</sub> and 0.025% Triton X-100 for 2 h at 23 °C. Bound tracer was isolated by centrifugation and the relative receptor affinities (RA) were calculated from a plot of bound insulin against receptor concentration as described elsewhere [17]. Human insulin represents the RA of 100%.

#### Animal experiments

Studies in rabbits were performed on non-diabetic, fasted, male New Zealand White rabbits, 0.5–3 years of age and weighing 2.5–3.5 kg, receiving subcutaneous injections of either an acylated insulin or NPH-insulin. At least 1 h before dosing, the rabbits


was 12 nmol of insulin per animal. Blood samples were drawn before and 1, 2, 4 and 6 h after injection. Glucose analysis was performed by the hexokinase method [18].

Euglycaemic glucose clamps were carried out in non-diabetic, conscious, female pigs, cross-bred from Danish Landrace, Yorkshire and Durok, 4–5 months of age and weighing 70–95 kg. Before the experiments the pigs were fasted overnight, for 18 h. Two catheters were inserted in the jugular veins, one for glucose infusion and one for blood sampling. The pigs were free to move in their pens during the clamp period. Five pigs received NPH-insulin and Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin in random order with an interval of 10 days. The dose was 216 nmol of insulin. The pigs were kept euglycaemic at their individual fasting glucose levels by infusion of a glucose solution (270 g/l) at a variable rate. Depending on changes in plasma glucose concentration obtained during frequent plasma glucose monitoring, the necessary adjustments of the glucose infusion were made empirically. Blood samples were collected in heparinized glass tubes every 15 min, plasma was separated, and glucose was determined within 1.5 min of blood sampling with a YSI (Yellow Springs Instruments) glucose analyser (glucose oxidase method).

## RESULTS


### Binding of acylated insulins to immobilized HSA

The interaction between albumin and insulins acylated with fatty acids at the  $\epsilon$ -amino group of Lys<sup>B29</sup> was studied using albumin immobilized on agarose. This method was chosen because the size of the ligands precludes performing binding studies by dialysis. Typical plots for binding of the insulins to immobilized HSA are shown in Figure 2. Scatchard plots are not linear, as exemplified in the inset to Figure 2, indicating that binding occurs at more than one class of sites. The initial part of the Scatchard plot is consistent with binding of at least 1 mol of Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin per mol of HSA with



**Figure 2** Binding of fatty acid acylated insulins to immobilized HSA

Various concentrations (0–150  $\mu$ M) of <sup>125</sup>I-(Tyr<sup>A14</sup>)-labelled insulins were equilibrated with 5  $\mu$ M of immobilized HSA at 23 °C. ■, Lys<sup>B29</sup>-decanoyl, des-(B30) insulin; △, Lys<sup>B29</sup>-



**Figure 3** Plots of bound/free insulin concentration ratios against HSA<sub>imm</sub> concentration


<sup>125</sup>I-(Tyr<sup>A14</sup>)-labelled insulins (2.5 nM) were equilibrated with 1–20  $\mu$ M immobilized HSA at 23 °C. □, Lys<sup>B29</sup>-decanoyl insulin; ■, Lys<sup>B29</sup>-decanoyl, des-(B30) insulin; △, Lys<sup>B29</sup>-dodecanoyl, des-(B30) insulin; ○, Lys<sup>B29</sup>-tetradecanoyl insulin; ●, Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin.

high affinity. The capacity of albumin for binding the insulins apparently exceeds 5 mol/mol, without any indication of saturation within the tested concentration range. However, the interpretation of binding data obtained at insulin concentrations above 10  $\mu$ M is difficult owing to extensive insulin self-association and to the relatively low solubility of the acylated insulin analogues in the applied buffer.

To quantify and compare the affinities of the fatty acid acylated insulins for HSA, <sup>125</sup>I-labelled insulins were equilibrated at 2.5 nM with various concentrations (1–20  $\mu$ M) of immobilized HSA. At these experimental conditions less than 0.25% of the albumin is occupied by an insulin molecule, and the first association constant,  $K_a$ , for binding of insulin to albumin can be estimated by:


$$K_a = \frac{B}{F} \frac{1}{[HSA_{imm}]}$$

where  $B/F$  is the ratio between bound and free <sup>125</sup>I-labelled insulin and  $[HSA_{imm}]$  is the total concentration of immobilized albumin [19]. Plots of  $B/F$  against  $[HSA_{imm}]$  are linear with slopes that estimate  $K_a$ . Representative plots are shown in Figure 3. The  $K_a$  for binding Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin to HSA is determined as  $2.4 \times 10^5 \text{ M}^{-1}$  by this approach. This value seems to be in good agreement with the estimate of  $K_a$  obtained by extrapolation of the Scatchard graph (Figure 2, inset) to the intercept with the ordinate axis [20,21]. Lys<sup>B29</sup>-acylated des-(B30) insulins have higher affinities for albumin than their full B-chain counterparts. The increase in  $-\Delta G$  for binding obtained by deletion of Thr<sup>B30</sup> is about 0.35 kcal/mol for the decanoyl and tetradecanoyl derivatives (Figure 4). The location of the C-terminal carboxylate group closer to the lipophilic side chain may favour formation of an ionic bond to a basic residue at the



**Figure 4** Correlation between  $K_a$  for binding of fatty acid acylated insulins to immobilized HSA and the number of carbon atoms in the fatty acid side chain

$K_a$  was estimated as the slope of linear plots of  $B/F$  against  $[HSA_{imm}]$  as shown in Figure 3. ●, Lys<sup>B29</sup>-acylated, des-(B30) insulins; ○, Lys<sup>B29</sup>-acylated insulins with full B-chain. The points shown are the means of at least two determinations.




**Figure 5** Displacement of Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin from immobilized HSA with lauric acid

<sup>125</sup>I-(Tyr<sup>A14</sup>)-labelled Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin (2.5 nM) was equilibrated with 10.1  $\mu$ M Mini-Leak HSA in the presence of 0.6  $\mu$ M to 2.5 mM lauric acid at 23 °C.

number of carbon atoms in the acyl chain is increased from 10 to 14, reflecting that non-polar interactions contribute to the binding. The gain in  $-\Delta G$  for binding obtained by extension of the fatty acid chain with one methylene group is 0.2–0.5 kcal/mol (Figure 4), which is in the region of one-half that reported for the long-chain free fatty acids [22]. Extension of the chain length to 16 carbon atoms does not increase the binding affinity any further. We note that human insulin *per se* does not bind with detectable affinity to immobilized HSA ( $K_a < 10^3$  M<sup>-1</sup>).

#### Competition with fatty acids

The influence of fatty acids on the binding of Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin to HSA is shown in Figure 5. A significant displacement of the insulin occurs in the presence of more than 1 mole of lauric acid per mol of HSA. Thus the trace



**Figure 6** Van't Hoff plot for the binding of Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin to immobilized HSA

<sup>125</sup>I-(Tyr<sup>A14</sup>)-labelled Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin (2.5 nM) was equilibrated with 1–10  $\mu$ M immobilized HSA at various temperatures (4–37 °C). The buffer was 5 mM Tris, pH 7.4, containing 100 mM NaCl and 0.025% (v/v) Triton X-100.  $K_a$  was estimated as the slope of linear plots of  $B/F$  against  $[HSA_{imm}]$  as shown in Figure 3. The points shown are the means of four determinations.

is occupied. A 50% displacement is obtained at a fatty acid to HSA<sub>imm</sub> concentration ratio of about 4, and the insulin derivative is quantitatively displaced as this ratio approaches 100. The results suggest that the fatty acid acylated insulin competes with long-chain fatty acids for binding at common sites. Alternatively the displacement of the acylated insulins by laurate might be due to a conformational change.


#### Temperature dependence and thermodynamic parameters

The temperature dependence of the association constant for binding of Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin to HSA is shown in Figure 6.  $K_a$  decreases with increasing temperature in the range 4–37 °C, in agreement with previous results for the interaction between HSA and fatty acids [21]. The  $K_a$  for binding of this insulin analogue to HSA at 37 °C is  $1 \times 10^5$  M<sup>-1</sup>. Hence at an HSA concentration of 0.6 mM, corresponding to the albumin level in human plasma, the bound fraction is 98.4%. The almost linear correlation between  $1/T$  and  $\ln K_a$  allows us to estimate the enthalpy change that accompanies binding from the van't Hoff equation,  $\ln K_a = \Delta H^\circ/RT + \text{constant}$  [23]. The change in free energy and entropy at 298 K can be obtained from the equations  $\Delta G^\circ = -RT \ln K_a$  and  $\Delta G^\circ = \Delta H^\circ - T\Delta S^\circ$ . The estimated values for  $\Delta G^\circ$ ,  $\Delta H^\circ$  and  $T\Delta S^\circ$  are  $-29.5$ ,  $-19.4$  and  $10.1$  kJ/mol, respectively, indicating that the association is driven by favourable changes in both enthalpy and entropy.

#### Effect profiles *in vivo*

The effect profiles of the fatty acid acylated insulins after subcutaneous injection into rabbits are shown in Figure 7(a). NPH-insulin, which is the most generally used long-acting insulin suspension in the treatment of diabetes, was given as a reference. The fall in blood glucose within the first hour after injection shows that the acylated insulins have a significantly slower onset of action than NPH-insulin. Furthermore, the time until maximal effect is generally longer for the acylated insulins than for NPH-insulin. However, this time cannot be determined for all insulins,






**Figure 7** Blood-glucose-lowering effect of fatty acid acylated insulins after subcutaneous injection into rabbits

(a) □, Lys<sup>B29</sup>-decanoyl insulin ( $n = 24$ ); ■, Lys<sup>B29</sup>-decanoyl, des-(B30) insulin ( $n = 36$ ); ▲, Lys<sup>B29</sup>-undecanoyl, des-(B30) insulin ( $n = 12$ ); △, Lys<sup>B29</sup>-dodecanoyl, des-(B30) insulin ( $n = 18$ ); ○, Lys<sup>B29</sup>-tridecanoyl, des-(B30) insulin ( $n = 4$ ); ●, Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin ( $n = 6$ ). The heavy line shows the effect of NPH-insulin ( $n = 34$ ). Changes in blood glucose are given as means  $\pm$  S.E.M. (b) Correlation between the relative affinities of the acylated insulins for HSA and the decrease in blood glucose 1 h after injection. Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin represents a relative affinity of 1.0.

the affinity of the acylated insulin for albumin, suggesting that the protracted effect of the acylated insulins is due to albumin binding.

The receptor affinity relative to human insulin for Lys<sup>B29</sup>-decanoyl insulin; Lys<sup>B29</sup>-decanoyl, des-(B30) insulin; Lys<sup>B29</sup>-dodecanoyl, des-(B30) insulin; and Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin was found to be 76%, 76%, 54% and 46% respectively; the RAs for Lys<sup>B29</sup>-undecanoyl, des-(B30) insulin and Lys<sup>B29</sup>-tridecanoyl, des-(B30) insulin were not determined. It has previously been shown that insulin analogues with 20–300% receptor affinity have the same biological potency *in vivo* [24]. To preclude the possibility that the diminished action on blood glucose is related to a decreased bioefficacy of the acylated insulins and to study the effect profile over a longer time course, we performed a 24 h euglycaemic glucose clamp after subcutaneous injection of 216 nmol Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin and NPH-insulin into pigs. The resulting profiles are shown in Figure 8. The cumulative glucose infusion (0–24 h) was the same after injection of Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin ( $2.5 \pm 1.3$  mol) and NPH-insulin ( $2.6 \pm 0.6$  mol), indicating that the two insulin preparations are equivalent *in vivo*



**Figure 8** Euglycaemic glucose clamp after subcutaneous injection into pigs

Blood glucose levels (means  $\pm$  S.D.; top) and glucose infusion rates (means  $\pm$  S.E.M.,  $n = 5$ ; bottom) during euglycaemic glucose clamp after subcutaneous injection of 216 nmol NPH-insulin (left) and Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin (right) into pigs.

for at least 18 h. However, Lys<sup>B29</sup>-tetradecanoyl, des-(B30) insulin showed a more protracted glucose utilization profile than NPH-insulin, the times to peak effect being  $6.4 \pm 2.2$  h and  $3.4 \pm 0.2$  h, respectively.

## DISCUSSION

Derivatization of the insulin molecule with albumin-binding ligands provides a new approach to protracting the blood-glucose-lowering effect after subcutaneous injection of the hormone. Albumin is the most abundant protein in the extracellular fluid. The concentration of HSA in human plasma is about 0.6 mM [25], whereas the level in subcutaneous interstitial fluid is about 60% of that in plasma [12]. The protein binds a wide variety of endogenous substances and drugs with binding constants that are typically in the order of  $10^4$ – $10^8$  M<sup>-1</sup> for organic anions, and about  $10^8$  M<sup>-1</sup> for long-chain fatty acids [7–10]. We have obtained insulins with affinities of  $10^4$ – $10^5$  M<sup>-1</sup> for HSA by acylation of the  $\epsilon$ -amino group of Lys<sup>B29</sup> with saturated fatty acids containing 10 to 16 carbon atoms.

## Binding mechanism

The binding of aromatic anions and fatty acids to albumin occurs by a combination of hydrophobic and ionic interactions [26–30]. In accord with this general mechanism, the C-terminal carboxylate group and the acyl side chain of the fatty acid acylated insulins seem to take part in the interaction with HSA. Thus the interaction between albumin and fatty acid acylated des-(B30) insulins is believed to involve the fatty acid carbon chain and the side chain (1 nitrogen plus 4 carbon atoms), the  $\alpha$ -carbon and the carboxylate group of Lys<sup>B29</sup>. The binding site apparently cannot adapt sufficiently for further non-polar inter-

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.